Immunotherapy Drugs Market Research Report
PREBOOK THIS REPORT - SAVE 10%

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

TO BE PUBLISHED : Jul 2021 | Pages : 215

Up to $525 off Prebook this report

Rising Prevalence of Chronic Diseases Such as Cancer to Boost Immunotherapy Drugs Market

Immunotherapy Drugs Market Size, Share, Trends Analysis Report by Product (Monoclonal Antibodies, Immune System Modulators, CAR-T Therapies, and Others); By Disease (Cancer, Autoimmune & Inflammatory Diseases, and Others); and Geography (North America, Europe, APAC, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021–2026

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

215 Pages

59 Tables

70 Charts

5 Regions

18 Countries

20 Companies

3 Market Segment

Immunotherapy Drugs Market Report Scope

Report Attribute Details
Base Year 2020
Forecast Year 2021 –2026
Market Segments Product (Monoclonal Antibodies, Immune System Modulators, CAR-T Therapies, and Others); Disease (Cancer, Autoimmune & Inflammatory Diseases, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, the UAE, South Africa, and Turkey

Scientific advances in the treatment of chronic diseases are witnessing a significant boost since the last decade, which is attributed to the rising prevalence of diseases such as cancer. Cancer is one of the leading causes of mortality across the globe. According to the World Health Organization (WHO), cancer accounted for around 10 million deaths across the globe in 2020. As immunotherapy has been proven to provide lasting benefits for terminal patients, it is becoming the highly preferred therapy especially for patients with 3rd to 4th stage of cancer.

Immunotherapy clinically improves the body’s immune system to fight cancer cells. It is the most revolutionary therapy with significant potential for cancer treatment. Owing to the significant increase in the incidence rate of cancer, the immunotherapy drugs market is witnessing an exponential growth. According to the National Cancer Institute, the incidence rate of cancer was 442.4 per 100,000 between 2013 and 2017 and the annual number of new cases is expected to reach around 29.5 million by 2040. This is projected to augment the market during the forecast period.

Significant Investment by Key Pharmaceutical Giants to Develop Novel Immunotherapies to Propel Market Growth

  • Rising focus of key companies to strengthen their pipeline drugs portfolio for cancer treatment to propel the immunotherapy drugs market size.
  • Increased funding in R&D of novel immunotherapies to fights against cancer and other autoimmune disease will boost the global cancer immunotherapy market.

Improved Reimbursement Scenario for Cancer Treatment

  • Increasing coverage for certain immunotherapy drugs by payors in emerging economies to contribute to the growth of the immunotherapy drugs market size.
  • Smooth reimbursement procedures in developed countries for life-saving drugs is expected to propel the demand for immunotherapy drugs for cancer.

Clinical Benefits Associated with Monoclonal Antibodies to Boost Segment Growth

Based on product type, the immunotherapy drugs market is categorized into monoclonal antibodies, immune system modulators, adoptive cell therapies, and others. The monoclonal antibody segment is anticipated to dominate the immunotherapy drugs market share during the forecast period in terms of revenue, which is attributed to their efficacy and potency to disrupt the cancer cell activity. The improved distribution network of manufacturers and green signal by the USFDA and other regulatory authorities to approve numerous monoclonal antibodies across the globe are expected to augment the expansion of this segment in the coming years.

Efforts Being Made in Public and Private Healthcare Sectors Aiming to Increase R&D for Cancer Treatment to Augment Growth of Cancer Segment

On the basis of disease indication, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, and others. Cancer accounted for the highest market share in 2020 and is likely to lead the share during the forecast period. Rising prevalence of cancer due to improved diagnostic techniques for the disease and improved reimbursement coverage for cancer immunotherapies are the key factors for the estimated high growth of this segment.

Increased Funding and Rise in Research Activities in US and China to Boost Market in Respective Regions

Based on region, the immunotherapy drugs market is segmented into North America, Europe, APAC, Latin America, and Middle East & Africa. North America accounted for the highest revenue in 2020, attributed by the rising focus of key manufacturers to strengthen the drugs pipeline profile to stay ahead in the cutthroat competition in the US. Moreover, improved treatment algorithm for cancer and autoimmune diseases makes immunotherapy a preferred therapy type in the US and Canada is projected to boost the market growth in North America.

Europe is considered to hold the second position in the immunotherapy market in terms of value. The strategic presence of key companies such as Novartis, Roche, and AstraZeneca are expected to boost the revenue generation in Europe. However, APAC is expected to reflect relatively higher CAGR during the forecast period, which is attributable to the growing awareness of various novel therapies for the treatment of chronic diseases. Rising healthcare expenditure of the population, improved regulatory policies, and launches of novel immunotherapies are expected to boost the market growth of Latin America and the Middle East & Africa.

Competition Landscape

The immunotherapy drugs market is highly dynamic with various small-size, mid-size and big companies offering a wide range of immunotherapies. Emergence of local & regional players with enhanced R&D capabilities and their improved distribution network are the key factors responsible for making the market fragmented and competitive. Various biopharmaceutical giants such as Sanofi are adopting the mergers and acquisition strategy to expand their product portfolio and to expand the accessibility across the globe, which is expected to propel the market for such companies in coming years and make the market more fragmented.

Some prominent players in the immunotherapy market include Merck & Co., Inc., Abbvie, Samsung Bioepis, Novartis AG, GlaxoSmithKline, Eli Lilly & Company, Genentech, Inc., Johnson & Jonson Services, LLC., Bristol-Myers Squibb, Pfizer, Inc., AstraZeneca, Teva Pharmaceuticals, and Amgen.

Who Would Be Interested in This Research:

  • Pharmaceutical & Biotech Companies
  • Healthcare Facilities
  • Public Health Organizations
  • Distributors
  • Raw Material Suppliers
  • Regulatory Authorities
  • Clinical Research Organizations
  • Drug Discovery & Clinical Development Service Providers
  • Academic Institutes & Research Institutes
  • Consulting Companies

Pre-book this research or participate in the study to gain exclusive access to data-driven insights and trends in the immunotherapy drugs market.

Download Free Sample
Read More

Select a license type that suits your business needs

Single User Licence
$3375.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$3825.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$4725.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1350.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date